Erlotinib has been approved as a third-line treatment for advanced non-small-cell lung
cancer (NSCLC) in British Columbia (BC). A cost-effectiveness analysis was conducted to …

Introduction: Erlotinib was recently approved in British Columbia (BC) as a second-line
treatment for advanced NSCLC. A cost-effectiveness analysis was conducted which …

OBJECTIVE: A PE analysis was performed to support the reimbursement request of erlotinib
in 2nd/3rd-line treatment of NSCLC in The Netherlands (NL). METHODS: Erlotinib and BSC …

Background Platinum-doublet, first-line treatment of locally advanced or metastatic non-
small cell lung cancer (NSCLC) is limited to 4–6 cycles. An alternative strategy used to …

Abstract Background The NCIC Clinical Trials Group conducted the BR. 21 trial, a
randomized placebo-controlled trial of erlotinib (an epidermal growth factor receptor tyrosine …

Introduction The purpose of this study was to describe treatment use patterns and outcomes
with single-agent erlotinib among patients with advanced Non–Small-cell lung cancer …

This study was designed to assess the cost-effectiveness of erlotinib compared with
docetaxel in the second-line management of advanced non-small-cell lung cancer (NSCLC) …

A majority of patients with lung cancer present with advanced disease: approximately 30%
with locally advanced disease and 45% with metastatic disease. The prognosis for these …

BACKGROUND: Lung cancer is the most common non-skin cancer and the leading cause of
cancer death among men and women in North America. More than half of all patients …

Several clinical and biological parameters are known to influence the efficacy of second-line
erlotinib therapy for nonsmall cell lung cancer (NSCLC), but their medico-economic impact …